Research and experimental development on natural sciences and engineering
MIM PHARMA AS
Revenue 2024
NOK 22
Operating profit
NOK −35,000
Equity
NOK −261,000
Incorporated
2013
Share capital
NOK 60,000
Financials
Total operating revenue
Operating profit (EBIT)
Income statement
| Post | 2024 | Trend |
|---|---|---|
| Total operating revenue | 22 | |
| Total operating costs | 35k | |
| Operating profit (EBIT) | −35k | |
| Net financial items | 0 | |
| Profit for the year | −35k |
Balance sheet
| Post | 2024 | Trend |
|---|---|---|
| Total assets | 59k | |
| of which current assets | 29k | |
| Equity | −261k | |
| Total liabilities | 320k |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.